HOME PRODUCTS SERVICES COMPANY CONTACT FAQ

oxaprozin (Daypro)

structure

Also Known As:

Daypro; 4,5-diphenyl-2-oxazolepropionic acid; Apo-Oxaprozin; Apotex brand of oxaprozin; CSC brand of oxaprozin; Danoprox; Dayrun; Pfizer brand of oxaprozin; Rhoxal-oxaprozin; Rhoxalpharma brand of oxaprozin; TRB brand of oxaprozin; Wy-21,743

Networked: 49 relevant articles (8 outcomes, 19 trials/studies)

Relationship Network

Drug Context: Research Results

Experts

1.	Inci, M Fatih: 1 article (05/2010)
2.	Kara, Isa M: 1 article (05/2010)
3.	Gümüş, Cesur: 1 article (05/2010)
4.	Polat, Serkan: 1 article (05/2010)
5.	Ince, Fatih: 1 article (05/2010)
6.	Heller, Barbara: 1 article (08/2004)
7.	Tarricone, Rosanna: 1 article (08/2004)
8.	Kean, Walter F: 1 article (08/2004)
9.	Goldkind, Lawrence: 1 article (01/2004)
10.	Beitz, Julie: 1 article (01/2004)

Related Diseases

1.	Pain (Aches) 01/01/1999 - "HRQOL was measured by the Medical Outcomes Study Short-Form-36 Health Survey (1-week recall period) at baseline and weeks 2 and 6. Data from the 2 trials were combined to assess differences across the 4 groups in 8 domains and 2 summary scores at baseline, and changes in HRQOL scores at weeks 2 and 6. At week 2, the oxaprozin group showed significantly greater improvement than the placebo group in role physical, vitality, and mental component summary (MCS) scores (P < 0.05), and in physical functioning, bodily pain, social functioning, and physical component summary (PCS) scores (P < 0.01). " 01/01/1999 - "At week 6, oxaprozin treatment resulted in significantly greater improvement than placebo in physical functioning, role physical, and bodily pain (P < 0.05); social functioning, role emotional, and mental health (P < 0.01); and vitality and MCS score (P < 0.001). " 03/01/1988 - "Oxaprozin-treated patients showed significant improvement in spontaneous pain of the vertebral spine and in morning stiffness after 6 weeks' treatment. " 01/01/1984 - "Assessments made on entry and after 4 and 8 weeks of treatment showed that in the oxaprozin group there were significant mean decreases, indicating improvement in patient's condition, with respect to observer's opinion, patient's opinion, pain intensity and activity impairment at both on-therapy visits. " 08/01/2004 - "Oxaprozin: kinetic and dynamic profile in the treatment of pain."
2.	Osteoarthritis 05/01/1992 - "Its spectrum of anti-inflammatory activity has been demonstrated in both in vitro and in vivo models.1 The majority of published clinical trials have focused on the use of oxaprozin (from Searle) in the treatment of osteoarthritis and rheumatoid arthritis." 04/01/1998 - "The results suggest that Oxaprozin is more effective than Diclofenac retard, a recognized standard therapy, when given for 6 weeks to patients with active osteoarthrosis." 04/01/1998 - "The present study should elucidate the efficacy, patient acceptability, and side effect profiles of Oxaprozin and Diclofenac retard when given to patients with active primary osteoarthrosis. " 01/01/1996 - "This 6-week, multicenter, double-masked, placebo-controlled study compared the efficacy, tolerability, and safety of the recommended starting dose of oxaprozin (1200 mg/d) and a 1500-mg/d dose of nabumetone in the treatment of patients with moderate-to-severe osteoarthritis (OA) of the knee. " 07/01/1995 - "This multicenter, 6-week, double-blind, placebo-controlled, parallel-group study compared the efficacy and safety of oxaprozin 1200 mg once daily with that of nabumetone 1000 mg once daily in patients with moderate-to-severe osteoarthritis (OA) of the knee. "
3.	Tendinopathy (Tendonitis) 01/01/1983 - "The results of this study indicate that oxaprozin is as effective and safe as phenylbutazone and superior to placebo in the treatment of patients with acute tendinitis and bursitis." 01/01/1983 - "The effects of 1,200 mg of oxaprozin once daily, 100 mg of phenylbutazone four times daily, and placebo were compared in the treatment of 125 patients with acute tendinitis and bursitis in a seven-day double-blind study at six clinical sites. " 01/01/1983 - "A multicenter, double-blind comparison of oxaprozin, phenylbutazone, and placebo therapy in patients with tendinitis and bursitis."
4.	Bursitis (Adhesive Capsulitis) 01/01/1983 - "The results of this study indicate that oxaprozin is as effective and safe as phenylbutazone and superior to placebo in the treatment of patients with acute tendinitis and bursitis." 01/01/1983 - "The effects of 1,200 mg of oxaprozin once daily, 100 mg of phenylbutazone four times daily, and placebo were compared in the treatment of 125 patients with acute tendinitis and bursitis in a seven-day double-blind study at six clinical sites. " 01/01/1983 - "A multicenter, double-blind comparison of oxaprozin, phenylbutazone, and placebo therapy in patients with tendinitis and bursitis."
5.	Inflammation 05/01/1979 - "The development of oxaprozin provided an opportunity to evaluate the control of inflammation in rheumatoid arthritis by a drug that can be administered once daily. " 07/01/1984 - "[Clinical evaluation of oxaprozin in the treatment of acute upper respiratory tract inflammations--a double-blind comparative study using ibuprofen as the control drug]." 08/01/2004 - "Oxaprozin (4,5-diphenyl-2-oxazolepropionic acid) is a non-steroidal anti-inflammatory drug (NSAID) which is effective in models of inflammation, pain and pyrexia. " 02/01/2002 - "Oxaprozin eye drops significantly reduced the signs of ocular inflammation elicited by sodium arachidonate on conjunctiva and iris. " 02/01/2002 - "The effects of eye drops containing a propionic acid derivative (oxaprozin) at 0.1% concentration on ocular inflammation produced by sodium arachidonate in the rabbit's eye were evaluated. "

Related Drugs and Biologics

1.	Aspirin (Acetylsalicylic Acid)
2.	Diclofenac (SR 38)
3.	nabumetone (nabumeton)
4.	Phenylbutazone (Butazolidin)
5.	Naproxen (Naprosyn)
6.	Ibuprofen (Motrin)
7.	Sulindac (Copal)
8.	Sodium
9.	Creatinine
10.	rofecoxib (Vioxx)

Related Therapies and Procedures

1.	Oral Surgery (Maxillofacial Surgery)